JPS6237017B2 - - Google Patents
Info
- Publication number
- JPS6237017B2 JPS6237017B2 JP59031877A JP3187784A JPS6237017B2 JP S6237017 B2 JPS6237017 B2 JP S6237017B2 JP 59031877 A JP59031877 A JP 59031877A JP 3187784 A JP3187784 A JP 3187784A JP S6237017 B2 JPS6237017 B2 JP S6237017B2
- Authority
- JP
- Japan
- Prior art keywords
- insulin
- present
- collagen
- administration
- atelocollagen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 64
- 102000004877 Insulin Human genes 0.000 claims description 32
- 108090001061 Insulin Proteins 0.000 claims description 32
- 229940125396 insulin Drugs 0.000 claims description 32
- 229920001436 collagen Polymers 0.000 claims description 17
- 108010035532 Collagen Proteins 0.000 claims description 16
- 102000008186 Collagen Human genes 0.000 claims description 16
- 239000000813 peptide hormone Substances 0.000 claims description 16
- 108010045569 atelocollagen Proteins 0.000 claims description 12
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 238000002360 preparation method Methods 0.000 description 10
- 239000008280 blood Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 238000009472 formulation Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 6
- 102000029816 Collagenase Human genes 0.000 description 4
- 108060005980 Collagenase Proteins 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 229960002424 collagenase Drugs 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 108060001064 Calcitonin Proteins 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010086019 Secretin Proteins 0.000 description 1
- 102100037505 Secretin Human genes 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 239000002933 immunoreactive insulin Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 229960002101 secretin Drugs 0.000 description 1
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59031877A JPS60174726A (ja) | 1984-02-21 | 1984-02-21 | 注射用医薬組成物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59031877A JPS60174726A (ja) | 1984-02-21 | 1984-02-21 | 注射用医薬組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS60174726A JPS60174726A (ja) | 1985-09-09 |
| JPS6237017B2 true JPS6237017B2 (fr) | 1987-08-10 |
Family
ID=12343261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP59031877A Granted JPS60174726A (ja) | 1984-02-21 | 1984-02-21 | 注射用医薬組成物 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS60174726A (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2537935B2 (ja) * | 1987-12-29 | 1996-09-25 | 住友製薬株式会社 | 生理活性物質の農縮・脱塩方法 |
| JPH04113394U (ja) * | 1991-03-22 | 1992-10-02 | 東海ゴム工業株式会社 | ホース脈動吸収装置 |
| WO2000030616A1 (fr) | 1998-11-20 | 2000-06-02 | Rtp Pharma Inc. | Microparticules dispersibles stabilisees par phospholipides |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6097918A (ja) * | 1983-11-01 | 1985-05-31 | Sumitomo Chem Co Ltd | インタ−フエロン持続性製剤 |
| JPS60112713A (ja) * | 1983-11-21 | 1985-06-19 | Sumitomo Chem Co Ltd | 有用な徐放性注射剤 |
| JPS60126217A (ja) * | 1983-12-14 | 1985-07-05 | Sumitomo Chem Co Ltd | 長期徐放性製剤 |
-
1984
- 1984-02-21 JP JP59031877A patent/JPS60174726A/ja active Granted
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6097918A (ja) * | 1983-11-01 | 1985-05-31 | Sumitomo Chem Co Ltd | インタ−フエロン持続性製剤 |
| JPS60112713A (ja) * | 1983-11-21 | 1985-06-19 | Sumitomo Chem Co Ltd | 有用な徐放性注射剤 |
| JPS60126217A (ja) * | 1983-12-14 | 1985-07-05 | Sumitomo Chem Co Ltd | 長期徐放性製剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS60174726A (ja) | 1985-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3122128B2 (ja) | ペプチド製剤 | |
| JP5819733B2 (ja) | 障害および疾患に対する全身治療のためのＴＧＦ−βスーパーファミリーメンバー含有タンパク質の末梢投与 | |
| JPH02101022A (ja) | 糖尿病治療用医薬組成物 | |
| JPH01501709A (ja) | カフェインの経鼻投与 | |
| JPH0780761B2 (ja) | 痛みのある疾患又はアレルギー性疾患の治療用組成物及び治療法 | |
| US4654324A (en) | Human proinsulin pharmaceutical formulations | |
| WO1985005036A1 (fr) | Traitement topique du diabete a l'aide d'insuline et d'un agent ameliorant la penetration applique sur la peau et recouvert d'une pastille | |
| JPH0637395B2 (ja) | ジペプタイド誘導体を含有する、筋萎縮性側索硬化症を治療するための薬剤 | |
| US6623732B1 (en) | Pharmaceutical formulation for nasal administration | |
| CN101317846B (zh) | 一种用于戒毒、镇痛的河豚毒素制剂 | |
| JP3697460B2 (ja) | Ｈｇｆ含有製剤 | |
| US5964224A (en) | Method for treating amyotrophic lateral sclerosis and a therapeutic agent therefor | |
| JP2002530353A5 (fr) | ||
| JPH08143449A (ja) | 徐放性局所麻酔用注射剤 | |
| JPS6237017B2 (fr) | ||
| US20050118241A1 (en) | Platform for transdermal formulations (ptf) | |
| KR20190117318A (ko) | 우수한 안정성을 갖는 데옥시콜린산 함유 주사제 조성물 및 이의 제조방법 | |
| JP5819734B2 (ja) | ＴＧＦ−βスーパーファミリーメンバー含有タンパク質の最小に侵襲性の全身送達のための組成物および方法 | |
| US5140008A (en) | Human growth hormone unit dose for the treatment of intoxicated individuals | |
| AU2001286092A1 (en) | Reduction of the electrocardiographic OT interval | |
| EP1317308A2 (fr) | Reduction de l'intervalle qt de l'electrocardioagramme | |
| JP2002529515A5 (fr) | ||
| JPH07507289A (ja) | 抗炎症剤 | |
| SU1706624A1 (ru) | Способ лечени опиумно-морфинных наркоманий | |
| AU704517B2 (en) | Anti-piroplasmotic agent |